The exploration of high-dose vitamin and mineral therapy in cancer has, as should be clear from our staff article, a long and contentious history. Vitamin C is certainly the best-studied of the vitamins that have been advocated for cancer treatment, and it plays a large role in the practice of Abram Hoffer, whose regimen formed the basis of the study by Lesperance and colleagues in British Columbia. The controversies about vitamin C have continued for years, in spite ofor perhaps because of-2 randomized trials that found no effect of vitamin C. Controversies on the details of the randomized studies and the protocols that they used have been left unresolved in the alternative cancer community, and several institutions continue to use high-dose vitamin C protocols. We very much appreciate Dr David Golde's perspective on the findings about vitamin C that have come out of his laboratory and out of other current research, which certainly provides a counterpoint to the continuing interest in vitamin C in alternative treatment. His findings on the uptake of vitamin C (in the form of dehydroascorbic acid) do need to be considered seriously, as does the evidence that the in vitro cytotoxicity of vitamin C in cancer is an artifact of the experimental setting. His enthusiasm for use of vitamin C in the treatment of various conditions, and in the prevention of cancer, is quite interesting and encouraging-but he does make the point, which other investigators have also made, that clinical studies with antioxidants in cancer prevention are proving difficult to conduct, with a resultant lack of evidence.
The study by Lesperance et al represents a substantial contribution to the evaluation of complementary medicine regimens. 1 Although the results did not come out as expected, Hoffer deserves the appreciation of those in the complementary medicine community on his willingness to contribute data on his patients to a study of this type. He also deserves recognition for his early work in the field of orthomolecular medicine, particularly the very early trials involving niacin in psychiatric disorders mentioned in his contribution. Hoffer's comments on the Lesperance study do provide some very interesting viewpoints into the evolution of his supplementation regimen, as well as into his early efforts to explore ways of validating his system within the context of a solo practice.
It is notable that Hoffer's system has evolved around vitamin C from the very beginning of its history, in 1977. It evolved without the strong research base that researchers-complementary and conventional alike-now are able to rely on, and appears to have had a component of clinical observation as well as background from the early literature correlating nutrition and cancer that began appearing in the 1980s. Our article on the history of vitamin C supplementation explains some of the controversial history of ascorbic acid in cancer treatment, and it is interesting to observe that Hoffer worked with Linus Pauling, the major early advocate of vitamin C as a cancer treatment in this country, in some of his early attempts at determining the significance of the outcomes in his patients.
Hoffer's early attempts at assessing survival among his patients, which involved comparing patients in his practice who did and did not adhere to his supplement regimen for 2 months or more, certainly represent weak experimental designs. They are, however, quite notable attempts at making a preliminary assessment of whether there is some reasonable ground to believe that patients treated with his supplementation regimen indeed survived longer than nontreated patients. They led, quite appropriately, to the study presently under discussion, which is a further advance in the assessment of orthomolecular supplementation. And although the Lesperance study will probably close the door on further exploration of this particular regimen for early breast cancer patients, we need to bear in mind that closing such doors is in fact a critical step in shaping the eventual research program in cancer complementary medicine. Hoffer's willingness to participate in a matching study of this sort, and his straightforward complementary regimen, may have precluded the immediate jump into the sort of randomized studies seen in the area of high-dose vitamin C research, which have left behind so much controversy. He may, in the end, find that another subgroup of his patients does benefit from his supplementation regimen, or that his regimen improves quality of life, and we would encourage him to keep doing serious preliminary studies of such subgroups. He may not, however, achieve these results. He still deserves the regard of the complementary and alternative cancer community for his early work in the field and for making serious attempts to evaluate the efficacy of his regimen.
Hoffer's comments on the unexpected discord that arose from his participation in this study-in sharp contrast to his very early experiences in the development of quantitative methods to assess thiamine fortification of flour-reflect some of the disturbing level of controversy that surrounds the development of assessment methods in complementary cancer medicine. The controversies attending the progress of the various vitamin C supplementation studies are also obvious, and their continuing power in some communities attests to the fact that these controversies do not disappear easily. Debu Tripathy's contribution presages some difficult problems that loom in the future for complementary and integrative cancer medicine, and makes me suspect that controversy in this field will not abate any time soon.
Dr Debu Tripathy is eminently qualified to comment on the problems of experimental design that plague evaluations of complementary cancer modalities-including those of the Lesperance study. He is a member of the Integrative Cancer Therapies Advisory Board and an important colleague for many of us in the complementary and alternative medicine community. He has published on the potentials of adding complementary medicine and traditional Asian medical techniques to the treatment of early stage breast cancer 2 and has designed studies to evaluate such techniques. He is also highly qualified in the world of conventional oncology and has written extensively in areas ranging from evaluation of chemotherapy agents 3 to multidisciplinary care in cancer. 4 Tripathy's contribution strongly states some features of the politics of research on complementary and integrative cancer medicine that are worth attending to. First, he points out that, in spite of all the effort, concern, and funds that have gone into the attempts of the medical community to assist cancer patients, very little has yet been done in the area of understanding and evaluating alternative treatments-despite the fact that so many cancer patients use these treatments. Second, he addresses an issue that has often been brought up by those in the alternative community, but seldom acknowledged by those involved in conventional medicine. He points out that although there is a great deal of funding available from industry for products that are associated with intellectual property rights, there is relatively very little available, mostly from government sources, for the products of nature, or of the great traditional medicine systems, that are not associated with intellectual property. Could this, for example, be a reason that the work of Israel and colleagues in the 1980s, a small randomized trial in which postmenopausal breast cancer patients who took vitamin A supplements had a significantly higher proportion of responders to chemotherapy than an unsupplemented group, 5 was never apparently followed up? I obviously don't know. But I do know, as Tripathy cogently argues, that the result of both of these realities-the urgent need to explore complementary cancer treatments using randomized trials and the relatively small amount of funding available to do so-necessarily leads the integrative medicine research agenda in a very challenging direction.
Tripathy points out some problems with the Lesperance study: as excellent a contribution as this study is, the case-control research protocol does have biases. These could include the potential reluctance of patients who seek supplementation to undergo radiation therapy. As a clinician who deals with patients seeking integrative care on a daily basis, I would also argue that such patients are in fact reluctant to undergo chemotherapy and hormonal therapy. Because no data were available to the degree to which the patients in the Lesperance study actually followed up on their recommended systemic therapy, it is possible that Hoffer's group may have taken advantage of these life-extending therapies to a lesser extent than did the conventional patients, which could result in a shortened survival potential for his group. Thus, although the Lesperance study will undoubtedly be quite influential in guiding the future research agenda, it has hidden sources of bias that do put some of its results in question.
Tripathy also argues that a proliferation of small randomized trials of alternative-or complementary or integrative-regimens of supplementation or of other treatment strategies will not move the field ahead very effectively. Because of their limited statistical power to discern clinically significant survival differences on the order of 10% to 20%, these studies may not ultimately provide the evidence-based rationale that would be needed for widespread adoption of integrative methods by the medical community. These studies would essentially be in competition for the attention of the medical community with the very-large-scale randomized conventional medicine trials involving thousands of patients and multiple treatment centers that are now typical of oncology studies. Tripathy suggests that the field of integrative cancer medicine may ultimately have to converge on the project of adopting one single supplementation regimen (or, perhaps I would suggest a more comprehensive an integrative regimen) that would be widely acceptable to the community, and easily implemented at multiple centers, in order to muster the resources needed to undertake even a single large-scale multicenter trial. Such a trial additionally needs the support of the conventional oncology community, and it also needs to be palatable to patients who would have to be randomized to either the treatment or a placebo treatment. The placebo treatment, moreover, would have to be unidentifiable as such, and would presumably have to include placebo supplements to circumvent a problem that may have been at work in the randomized vitamin C trials of patients taking supplements on their own. The acceptability of randomization to the patients involved is another matter, and one that is perhaps even more challenging. One proposed randomized trial of an alternative cancer treatment failed at the point of accrual and has already had to be turned into a single-arm prospective study, with all the obvious biases of self-selection that this involves, because the patients involved were not willing to be randomized to the conventional treatment-only arm of the study. Given that so many patients perceive alternative or integrative medicine as potentially beneficial to their health, and because most have only a single chance at surviving their cancer, which of them will actually want to undertake a placebo treatment?
Looking at the project Tripathy proposes in the context of clinical work raises even more unsettling questions. How will the integrative cancer community manage to settle on one single regimen? The politics and emotionality that we have noted attend the area of alternative cancer treatment, and the rugged independence of many alternative and integrative practitioners, suggest that such a process will be difficult, if not bloody. I would suggest that there will need to be many more small-scale research projects before a single program will emerge that will be widely acceptable in the community. What will happen with the other integrative programs during the time that such a large-scale trial is undertaken? It can't be expected that they will disappear, particularly with the interest of patients in experimenting with such regimens. As the understanding of cancer biology grows, we note that integrative regimens evolve in sophistication and in biological rationale. Will the single regimen become outdated during the several years that it would take to complete the trial? And what will be the fate of patients who have other types of cancers besides the particular cancer type and stage that is under investigation? Other questions arise: will the medical community at large actually accept a trial of an integrative regimen, or will they want large-scale trials of each component of the regimen, in order to narrow it down to only the essentials in a quest for cost-effectiveness and ease of treatment? Will such limitations hinder the value of synergisms inherent in more comprehensive approaches? Will there be sufficient funding available for all these trials? What will patients do while they are awaiting the results of dozens and dozens of these trials? If the present reality persists, they certainly will not refrain from seeking integrative programs, or even from self-directed supplementation, because while these patients wait for more conclusive answers to randomized trials, their lives continue to slip away. The evolution of the program of research in integrative cancer care during the next decade, in the present environment of the large-scale multicenter trial, will be fascinating to watch, and it is unlikely to be as calm and agreeable a process as Hoffer recounts in his description of the historic development of assessments for thiamine fortification in the flour industry.
